Home > Insider Trading > Filing (0001628280-23-023651)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1437402	Ardelyx Inc.	ARDX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1815433	Robert Blanks	C/O Ardelyx, Inc. 400 Fifth Avenue, Suite 210 Waltham MA 02451	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-06-23	33,333	$3.42	299,467	No	4	M	Direct
Common Stock	Disposition	2023-06-23	33,333	$3.63	266,134	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-06-23	33,333	$0.00	33,333	$3.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2014-07-18	2023-07-18	No	4	M	Direct

Footnotes

This transaction relates an option that would have expired on July 18, 2023 and does not result in a reduction of shares held outright by the Reporting Person. The shares acquired upon the exercise of the option were sold pursuant to a Rule 10b5-1 stock trading plan adopted by the Reporting Person on March 24, 2023. accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
This transaction was executed in multiple trades in prices ranging from $3.62 to $3.70, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option, which was granted on July 18, 2013, and has an expiration date of July 18, 2023, is fully vested and exercisable.